(Q38800172)

6 September 2017

title

Ketamine for treatment-resistant depression: recent developments and clinical applications (English)

1 reference

treatment-resistant depression

6 September 2017

main subject

1 reference

Jaclyn Schwartz

1

1 reference

6 September 2017

James W Murrough

series ordinal

2

1 reference

6 September 2017

Dan V Iosifescu

series ordinal

3

1 reference

6 September 2017

language of work or name

English

0 references

publication date

6 April 2016

1 reference

Evidence-Based Mental Health

6 September 2017

published in

1 reference

6 September 2017

volume

19

1 reference

6 September 2017

issue

2

1 reference

6 September 2017

page(s)

35-38

1 reference

Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Is treatment-resistant depression a useful concept?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Ketamine for treatment-resistant unipolar depression: current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Ketamine administration in depressive disorders: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

How does ketamine elicit a rapid antidepressant response?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

The promise of ketamine for treatment-resistant depression: current evidence and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Ketamine safety and tolerability in clinical trials for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Assessing the risk factors for difficult-to-treat depression and treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Antidepressant actions of ketamine: from molecular mechanisms to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

A randomized controlled trial of intranasal ketamine in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Suicide and suicidal behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Does ketamine have anti-suicidal properties? Current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

The role of ketamine in treatment-resistant depression: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Neural correlates of change in major depressive disorder anhedonia following open-label ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

The impact of primary care: a focused review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FEB-2016-102355

21 January 2018

Identifiers

DOI

10.1136/EB-2016-102355

1 reference

6 September 2017

1 reference